Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients-Reference-Cited by-同舟云学术

Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients

Published:2023-08 Issue: Volume:178 Page:105-113
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Paster Irasema Concepcion,Zeng Jiping,Recio-Boiles Alejandro,Chipollini Juan

Publisher

Elsevier BV

Subject

Urology

Reference23 articles.

1. Surveillance Research Program, National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer. Accessed February 19, 2021. https://seer.cancer.gov/statfacts/html/urinb.html.

2. Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202-205. 10.1016/j.eururo.2005.04.006.

3. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial;Griffiths;J Clin Oncol,2011

4. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med,2003

5. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies;Sherif;Eur Urol,2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Age, Period, Cohort, Region, Race, and Health Services on Bladder Cancer Mortality in Brazil: A 23-Year Ecological Study;Cancers;2024-08-31